Zymeworks stock surges 14% on license deal with Jazz for cancer drug zanidatamab
seekingalpha.com
finance
2022-10-19 10:35:36

Florin1605 Jazz Pharmaceuticals (NASDAQ:JAZZ) signed a licensing agreement for development and commercialization rights to Zymeworks' (NYSE:ZYME) cancer drug zanidatamab in certain regions. Under the agreement, Jazz will pay $50M upfront, after US antitrust clearance, and get exclusive license to develop and sell zanidatamab in the U.S., Europe, Japan and all other territories except for those Asia/Pacific territories which Zymeworks had licensed to BeiGene (NASDAQ:BGNE), the companies said in a statement on Wednesday.
